mhurhangee/ep-ind-claims huggingface dataset:
A pharmaceutical composition comprising or made from a DPP-4 inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine free base, a partner drug which is metformin hydrochloride, and one or more pharmaceutical excipients, and a nucleophilic and/or basic agent for stabilizing said DPP-4 inhibitor against degradation, wherein the nucleophilic and/or basic agent is a basic amino acid having an intramolecular amino group and alkaline characteristics, which is L-arginine, wherein the pharmaceutical composition is in the dosage form of a mono-layer tablet which comprises or is obtainable from a mixture comprising any one of the following amounts, or of active ingredients and L-arginine: 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine free base, 500 mg metformin hydrochloride, and 12.5 mg L-arginine; 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -aminopiperidin-1-yl)-xanthine free base, 850 mg metformin hydrochloride, and 21.2 mg L-arginine; 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -aminopiperidin-1-yl)-xanthine free base, 1000 mg metformin hydrochloride, and 25 mg L-arginine; with the disclaimer that the mono-layer tablet does not comprise a film coat. wherein the nucleophilic and/or basic agent is a basic amino acid having an intramolecular amino group and alkaline characteristics, which is L-arginine, wherein the pharmaceutical composition is in the dosage form of a mono-layer tablet which comprises or is obtainable from a mixture comprising any one of the following amounts, or of active ingredients and L-arginine: 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine free base, 500 mg metformin hydrochloride, and 12.5 mg L-arginine; 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -aminopiperidin-1-yl)-xanthine free base, 850 mg metformin hydrochloride, and 21.2 mg L-arginine; 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -aminopiperidin-1-yl)-xanthine free base, 1000 mg metformin hydrochloride, and 25 mg L-arginine; 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine free base, 500 mg metformin hydrochloride, and 12.5 mg L-arginine; 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -aminopiperidin-1-yl)-xanthine free base, 850 mg metformin hydrochloride, and 21.2 mg L-arginine; 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3- -aminopiperidin-1-yl)-xanthine free base, 1000 mg metformin hydrochloride, and 25 mg L-arginine; with the disclaimer that the mono-layer tablet does not comprise a film coat.
A solid lip cosmetic, comprising: (a) 25 to 45% by mass of hydrogenated polyisobutene; (b) 20 to 70% by mass of one or more methyl phenyl silicones that separate at 25 °C when mixed with (a); (c) 1 to 20% by mass of neopentyl glycol dicaprate, as the compatibility modifier, which modifies the compatibility of component (a) and component (b), and (d) 3 to 12% by mass of wax. (a) 25 to 45% by mass of hydrogenated polyisobutene; (b) 20 to 70% by mass of one or more methyl phenyl silicones that separate at 25 °C when mixed with (a); (c) 1 to 20% by mass of neopentyl glycol dicaprate, as the compatibility modifier, which modifies the compatibility of component (a) and component (b), and (d) 3 to 12% by mass of wax.
An access point name APN authorization method, comprising: determining, by a network device, a target APN of user equipment, UE, and a type of an access network that the UE currently accesses. wherein the network device is a non 3rd Generation Partnership Project non-3GPP access gateway; obtaining, by the network device, information about an authorized access network type corresponding to the target APN of the UE, comprising: receiving, by the network device, subscription data of the UE sent by a home subscriber server, HSS, wherein the subscription data of the UE comprises the information about the authorized access network type corresponding to the target APN of the UE; and determining, by the network device according to the type of the access network that the UE currently accesses and the information about the authorized access network type corresponding to the target APN of the UE, whether the target APN of the UE is authorized. determining, by a network device, a target APN of user equipment, UE, and a type of an access network that the UE currently accesses. wherein the network device is a non 3rd Generation Partnership Project non-3GPP access gateway; obtaining, by the network device, information about an authorized access network type corresponding to the target APN of the UE, comprising: receiving, by the network device, subscription data of the UE sent by a home subscriber server, HSS, wherein the subscription data of the UE comprises the information about the authorized access network type corresponding to the target APN of the UE; and determining, by the network device according to the type of the access network that the UE currently accesses and the information about the authorized access network type corresponding to the target APN of the UE, whether the target APN of the UE is authorized. receiving, by the network device, subscription data of the UE sent by a home subscriber server, HSS, wherein the subscription data of the UE comprises the information about the authorized access network type corresponding to the target APN of the UE; and determining, by the network device according to the type of the access network that the UE currently accesses and the information about the authorized access network type corresponding to the target APN of the UE, whether the target APN of the UE is authorized.
Belt that is continuously closed in the longitudinal direction, in particular a round baler belt, having a core region, and at least one peripheral region (13; 14) arranged transversely to the longitudinal direction, the peripheral region (13; 14) having, at least sectionally, a protective element which is incorporated into the material of the peripheral region (13;14), characterized in that the core region is continuously wound.
An organic EL element comprising: a laminate comprising: a pair of mutually opposing electrodes, and an organic luminescent material layer comprising an organic material, the organic luminescent material layer disposed between the pair of mutually opposing electrodes; a sealing structure that shields the laminate from the outside air; and a moisture reactive composition disposed within the sealing structure, the moisture reactive composition comprising a moisture-reactive polysiloxane comprising a main chain and one or more side chains, wherein the main chain and/or the one or more side chains comprise a group represented by the formula: -MX m Y n; and wherein: M is selected from the group consisting of a multivalent metal atom, B, and P=O; X is a hydrogen atom, or a substituted or nonsubstituted alkyl, alkenyl or alkoxy group; Y is a substituted or nonsubstituted alkoxy, siloxy, carboxyl, or diketolate group; m is from 1 to 3; and n is from 0 to 2. a laminate comprising: a pair of mutually opposing electrodes, and an organic luminescent material layer comprising an organic material, the organic luminescent material layer disposed between the pair of mutually opposing electrodes; a sealing structure that shields the laminate from the outside air; and a moisture reactive composition disposed within the sealing structure, the moisture reactive composition comprising a moisture-reactive polysiloxane comprising a main chain and one or more side chains, wherein the main chain and/or the one or more side chains comprise a group represented by the formula: -MX m Y n; and wherein: M is selected from the group consisting of a multivalent metal atom, B, and P=O; X is a hydrogen atom, or a substituted or nonsubstituted alkyl, alkenyl or alkoxy group; Y is a substituted or nonsubstituted alkoxy, siloxy, carboxyl, or diketolate group; m is from 1 to 3; and n is from 0 to 2. a pair of mutually opposing electrodes, and an organic luminescent material layer comprising an organic material, the organic luminescent material layer disposed between the pair of mutually opposing electrodes; a sealing structure that shields the laminate from the outside air; and a moisture reactive composition disposed within the sealing structure, the moisture reactive composition comprising a moisture-reactive polysiloxane comprising a main chain and one or more side chains, wherein the main chain and/or the one or more side chains comprise a group represented by the formula: -MX m Y n; and wherein: M is selected from the group consisting of a multivalent metal atom, B, and P=O; X is a hydrogen atom, or a substituted or nonsubstituted alkyl, alkenyl or alkoxy group; Y is a substituted or nonsubstituted alkoxy, siloxy, carboxyl, or diketolate group; m is from 1 to 3; and n is from 0 to 2. M is selected from the group consisting of a multivalent metal atom, B, and P=O; X is a hydrogen atom, or a substituted or nonsubstituted alkyl, alkenyl or alkoxy group; Y is a substituted or nonsubstituted alkoxy, siloxy, carboxyl, or diketolate group; m is from 1 to 3; and n is from 0 to 2.
A light source having a plurality of light elements and a control system for controlling said plurality of light elements, wherein the control system comprises: - a plurality of light element controllers, each connected to a respective one of said light elements, and arranged to obtain light element data; and - a bus interface, which is connected to said light element controllers via a light source bus, wherein said bus interface is arranged to provide said light element controllers with a general command, wherein said light element controllers are arranged to generate light element drive signals on basis of the general command and said light element data, characterised in that: said light element controllers each comprise a symbol tag interpreter and is tagged with at least one symbol tag, wherein at least one light element controller comprises a plurality of symbol tags or wherein a plurality of light element controllers comprise a corresponding symbol tag, wherein said general command each include at least one symbol tag, and wherein there are several different types of symbol tags, and wherein said symbol tag interpreter comprises a symbol tag comparator which is arranged to compare a symbol tag received in said general command with said at least one symbol tag that the light element controller is tagged with. - a plurality of light element controllers, each connected to a respective one of said light elements, and arranged to obtain light element data; and - a bus interface, which is connected to said light element controllers via a light source bus,
A method of preparing a biological specimen on a substrate for examination, the method comprising: (a) positioning the substrate with respect to a surface so that the biological specimen faces the surface, and so that the substrate and the surface are substantially parallel and form a separation; (b) sequentially dispensing (i) a first fixative solution, (ii) a first stain solution, (iii) a second stain solution, and (iv) a first rinse solution into the separation between the substrate and the surface in an amount sufficient to contact the specimen and the surface; and (c) after dispensing each one of solutions (i), (ii), (iii), and (iv) in step (b), and before dispensing the next one of solutions (i), (ii), (iii), and (iv) in step (b): performing at least a first agitation cycle, wherein the first agitation cycle comprises changing the distance between the substrate and surface while the dispensed solution contacts the specimen for the duration of the first agitation cycle; and removing the dispensed solution from the separation and from contacting the specimen. (a) positioning the substrate with respect to a surface so that the biological specimen faces the surface, and so that the substrate and the surface are substantially parallel and form a separation; (b) sequentially dispensing (i) a first fixative solution, (ii) a first stain solution, (iii) a second stain solution, and (iv) a first rinse solution into the separation between the substrate and the surface in an amount sufficient to contact the specimen and the surface; and (c) after dispensing each one of solutions (i), (ii), (iii), and (iv) in step (b), and before dispensing the next one of solutions (i), (ii), (iii), and (iv) in step (b): performing at least a first agitation cycle, wherein the first agitation cycle comprises changing the distance between the substrate and surface while the dispensed solution contacts the specimen for the duration of the first agitation cycle; and removing the dispensed solution from the separation and from contacting the specimen. performing at least a first agitation cycle, wherein the first agitation cycle comprises changing the distance between the substrate and surface while the dispensed solution contacts the specimen for the duration of the first agitation cycle; and removing the dispensed solution from the separation and from contacting the specimen.
A method that facilitates cell resource management, said method being performed by an apparatus in a base station (330, 1100) and comprising permitting different and flexible cell metric operation levels for different sub-bands by: dividing a communications band of a cell into a plurality of sub-bands; grouping sub-bands into a plurality of groups such that the sub-bands in each group are composed of sub-bands with the same or similar operational characteristics, associating a cell metric operation level to each group such that at least two of the plurality of groups are associated with cell metric operation levels that are different from one another, wherein the cell metric is an uplink load metric and wherein the uplink load metric comprises at least one of interference over thermal, IoT, and rise over thermal, RoT; and generating an uplink load metric value for each sub-band and, for each sub-band group, averaging the uplink load metric values over the entire set of sub-bands of the given group, and comparing the group average against the cell metric operation level associated to said group to generate load control commands on a group basis for controlling the transmission power of at least one UE. dividing a communications band of a cell into a plurality of sub-bands; grouping sub-bands into a plurality of groups such that the sub-bands in each group are composed of sub-bands with the same or similar operational characteristics, associating a cell metric operation level to each group such that at least two of the plurality of groups are associated with cell metric operation levels that are different from one another, wherein the cell metric is an uplink load metric and wherein the uplink load metric comprises at least one of interference over thermal, IoT, and rise over thermal, RoT; and generating an uplink load metric value for each sub-band and, for each sub-band group, averaging the uplink load metric values over the entire set of sub-bands of the given group, and comparing the group average against the cell metric operation level associated to said group to generate load control commands on a group basis for controlling the transmission power of at least one UE.
A recombinant expression vector, comprising an expression cassette comprising a hamster GAPDH promoter, operably linked to an exogenous gene of interest, further comprising a regulatory element that (a) is at least 95% identical to the nucleic acid sequence set forth in SEQ ID NO:35; and (b) is operably linked to the promoter, wherein the regulatory element is in the plus orientation. (a) is at least 95% identical to the nucleic acid sequence set forth in SEQ ID NO:35; and (b) is operably linked to the promoter,
A master cylinder apparatus, including a base member, to which an operation of a brake operator is inputted, the base member including flow passages (9a, 9b, 9e) for a brake fluid therein, comprising: a master cylinder that is provided to the base member and generates a fluid pressure when the operation of the brake operator is inputted thereto; three solenoid valves (4, 5, 6) that are mounted on one surface of the base and open and close the flow passages (9a, 9b, 9e), wherein two (4, 5) of the solenoid valves (4, 5, 6) are arranged symmetrically across a center axis in an axial direction of the master cylinder when viewed from a direction vertical to the one surface of the base member, characterized in that two pressure sensors (7, 8) for detecting brake fluid pressures in the flow passages (9a, 9b) are mounted on the one surface of the base member, and the three solenoid valves (4, 5, 6) and one of the pressure sensors are arranged to form corners of a quadrilateral (L1, L2, L3, L4), and the other of the pressure sensors is arranged inside the quadrilateral (L1, L2, L3, L4). a master cylinder that is provided to the base member and generates a fluid pressure when the operation of the brake operator is inputted thereto; three solenoid valves (4, 5, 6) that are mounted on one surface of the base and open and close the flow passages (9a, 9b, 9e), wherein two (4, 5) of the solenoid valves (4, 5, 6) are arranged symmetrically across a center axis in an axial direction of the master cylinder when viewed from a direction vertical to the one surface of the base member, characterized in that two pressure sensors (7, 8) for detecting brake fluid pressures in the flow passages (9a, 9b) are mounted on the one surface of the base member, and the three solenoid valves (4, 5, 6) and one of the pressure sensors are arranged to form corners of a quadrilateral (L1, L2, L3, L4), and the other of the pressure sensors is arranged inside the quadrilateral (L1, L2, L3, L4).
A system comprising: a pixel including a diffusion layer within a cap layer, wherein the diffusion layer defines a front side and an illumination side opposite the front side with an absorption layer operatively connected to the illumination side as well as the diffusion and cap layers (106, 108); and a set of alternating oxide and nitride layers deposited on the front side of the cap and diffusion layers (108, 106), wherein the pixel includes an avalanche photodiode structure wherein a field control layer is disposed in contact with the cap layer opposite from the set of alternating oxide and nitride layers, wherein a grading layer is disposed in contact with the field control layer opposite the cap layer, and wherein the grading layer is in contact with the absorption layer. a pixel including a diffusion layer within a cap layer, wherein the diffusion layer defines a front side and an illumination side opposite the front side with an absorption layer operatively connected to the illumination side as well as the diffusion and cap layers (106, 108); and a set of alternating oxide and nitride layers deposited on the front side of the cap and diffusion layers (108, 106), wherein the pixel includes an avalanche photodiode structure wherein a field control layer is disposed in contact with the cap layer opposite from the set of alternating oxide and nitride layers, wherein a grading layer is disposed in contact with the field control layer opposite the cap layer, and wherein the grading layer is in contact with the absorption layer.
A composition comprising a first antibody, or antigen binding fragment thereof, that binds Factor P, and a second antibody, or antigen binding fragment thereof, that binds C5, wherein said first antibody, or antigen binding fragment thereof, has the heavy and light chain variable domain sequence selected from the group consisting of a VH sequence of SEQ ID NO. 175 and a VL sequence of SEQ ID NO. 176; a VH sequence of SEQ ID NO. 7 and a VL sequence of SEQ ID NO. 8; a VH sequence of SEQ ID NO. 91 and a VL sequence of SEQ ID NO. 92; a VH sequence of SEQ ID NO. 105 and a VL sequence of SEQ ID NO. 106; a VH sequence of SEQ ID NO. 119 and a VL sequence of SEQ ID NO. 120; a VH sequence of SEQ ID NO. 189 and a VL sequence of SEQ ID NO. 190; a VH sequence of SEQ ID NO. 203 and a VL sequence of SEQ ID NO. 204; a VH sequence of SEQ ID NO. 217 and a VL sequence of SEQ ID NO. 218; and a VH sequence of SEQ ID NO. 231 and a VL sequence of SEQ ID NO. 232; and said second antibody or antigen binding fragment thereof that binds C5, has the heavy and light chain variable domain sequence selected from the group consisting of a VH sequence of SEQ ID NO. 416 and a VL sequence of SEQ ID NO. 417, a VH sequence of SEQ ID NO. 432 and a VL sequence of SEQ ID NO. 433; a VH sequence of SEQ ID NO. 448 and a VL sequence of SEQ ID NO. 449; a VH sequence of SEQ ID NO. 460 and a VL sequence of SEQ ID NO. 461; and a VH sequence of SEQ ID NO. 476 and a VL sequence of SEQ ID NO. 477, wherein said composition inhibits the alternative complement pathway.
A process for the biocatalytic cyclization of a compound of the formula in the presence of a cyclase which has an amino acid sequence as shown in SEQ ID No. 2 or which has at least 95% sequence identity to SEQ ID No. 2; wherein the compound of the formula is reacted to give the compound of the formula